Contract 36E79725D0014
Accord Biopharma, Inc. · Department Of Veterans Affairs · January 23, 2025
Accord Biopharma, Inc. was awarded a federal contract by Department Of Veterans Affairs on January 23, 2025 for an undisclosed amount of work in pharmaceutical preparation manufacturing. It was awarded under full and open competition. The contract has been modified 6 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on April 14, 2026. If all options are exercised, the contract could reach $27.63 million.
Contract details
- PIID
- 36E79725D0014
- Award type
- —
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- First action
- January 23, 2025
- Latest action
- April 14, 2026
Description
THIS MODIFICATION IS ISSUED TO INCORPORATE ACCORD BIOPHARMA INC'S 2026 SUBCONTRACTING PLAN FOR THE PERIOD OF APRIL 1, 2026 TO MARCH 31, 2027 INTO NATIONAL CONTRACT 36E79725D0014.
Modification timeline
-
April 14, 2026Mod P00006THIS MODIFICATION IS ISSUED TO INCORPORATE ACCORD BIOPHARMA INC'S 2026 SUBCONTRACTING PLAN FOR THE PERIOD OF APRIL 1, 2026 TO MARCH 31, 2027 INTO NATIONAL CONTR$0
-
April 14, 2026Mod P00005THIS MODIFICATION IS ISSUED TO INCORPORATE AN NDC ADDITION AND DELETION INTO NATIONAL CONTRACT 36E79725D0014.$0
-
March 17, 2026Mod P00004THIS MODIFICATION IS ISSUED TO INCORPORATE A NOVATION AGREEMENT INTO NATIONAL CONTRACT 36E79725D0014.$0
-
March 10, 2026Mod P00003THIS MODIFICATION IS ISSUED TO EXERCISE OPTION YEAR 1 ON NC 36E79725D0014 WITH A PERIOD OF PERFORMANCE OF 4/11/2026 TO 4/10/2027.$0
-
February 5, 2026Mod P00002THIS MODIFICATION IS ISSUED TO INCORPORATE AN NDC ADDITION INTO NC 36E79725D0014.$0
-
November 21, 2025Mod P00001THIS MODIFICATION IS ISSUED TO INCORPORATE 2026 FEDERAL CEILING PRICES FOR NC 36E79725D0014.$0
-
January 23, 2025Base awardNEW AWARD FOR PEGFILGRASTIM WITH COHERUS BIOSCIENCES, INC. ORDERING PERIOD IS APRIL 11, 2025, TO APRIL 10, 2026, WITH FOUR ONE-YEAR OPTIONS.$0
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Petnet Solutions, Inc. | Department Of Veterans Affairs | April 1, 2026 | $387.4K |
| Eli Lilly And Company | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Exelan Pharmaceuticals Inc | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Cardinal Health 414, Llc | Department Of Veterans Affairs | April 1, 2026 | $122.9K |
| Guardian Pharmacy Of Indianapolis Nuclear, Llc | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Jubilant Draximage Inc | Department Of Veterans Affairs | April 1, 2026 | $0 |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 53,729 | $99.76B |
| 2 | Pfizer Inc | 4,613 | $28.68B |
| 3 | Merck Sharp & Dohme Llc | 391 | $21.58B |
| 4 | Modernatx, Inc. | 3 | $8.20B |
| 5 | Sanofi Vaccines Us Inc. | 5,248 | $7.76B |
| 6 | Glaxosmithkline, Llc | 1,418 | $7.22B |
| 7 | Merck Sharp & Dohme Corp. | 349 | $5.33B |
| 8 | Pfizer Inc. | 3,842 | $4.83B |
| 9 | Eli Lilly And Company | 18 | $4.67B |
| 10 | Amerisourcebergen Drug Corp | 497 | $3.23B |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 36E79725D0014?
Contract 36E79725D0014 is a federal contract awarded to Accord Biopharma, Inc. by Department Of Veterans Affairs on January 23, 2025 for an undisclosed amount of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 6 times since the base award.
Who won contract 36E79725D0014?
Accord Biopharma, Inc. won contract 36E79725D0014 from Department Of Veterans Affairs.
How much is contract 36E79725D0014 worth?
Contract 36E79725D0014 has obligated $0 to date but carries a potential ceiling of $27.63 million if fully funded and all options are exercised.